Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim
compared to vancomycin. Patients will receive either iclaprim or vancomycin for 5 to 14 days.
Patients will be evaluated daily up to early time point (ETP), then every 48 to 72 hours
through the end of treatment. Patients will also be evaluated at the test of cure (TOC) visit
(7 to 14 days post-EOT), and will have a Late Follow-Up (LFU) visit (28 to 32 days post-first
dose).

Inclusion Criteria:

1. written informed consent;

2. ≥18 years of age;

3. a bacterial infection of the skin with a lesion size area of at least 75 cm2;

4. a major cutaneous abscess, cellulitis/erysipelas, and/or wound infections;

5. the presence of purulent or seropurulent drainage or at least three signs and symptoms
of infection (discharge, erythema, swelling, warmth, or pain).

Exclusion Criteria:

1. severely impaired arterial blood supply such that amputation of the infected
anatomical site is likely;

2. infected diabetic foot ulcers;

3. infected decubitus ulcers;

4. necrotizing fasciitis or gangrene;

5. uncomplicated skin or skin structure infection;

6. infections associated with a prosthetic device;

7. suspected or confirmed osteomyelitis;

8. conditions requiring systemic anti-microbial treatment, prophylaxis, or suppression
therapy.